Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 100(18): e25782, 2021 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-33950973

RESUMO

RATIONALE: Spindle cell lipoma is a rare, uncommon type of benign lipomatous tumor, a distinct group of lipomas composed of mature adipocytes, uniform spindle cells, and multinucleated giant cells associated with ropey collagen. Immunohistochemically, spindle cell lipoma is characterized by the diffuse expression of CD34. PATIENT CONCERNS: We present a rare case of a 56-year-old man who complained of vomiting out of a smooth and giant mass in the oral cavity provoked by an intra-abdominal pressure increase. Oral examination revealed an elongated mass protruding from the mouth. Computed tomography of the patient showed a mass from left pyriform to oral cavity, with 2.38 × 2.78 × 16.86 cm in size. The flexible fiberscope showed that the pedicle of the elongated mass originated from the posterior wall of the hypopharynx, corresponding to the left pyriform fossa. DIAGNOSIS: Histopathologically, the tumor was mainly composed of hyperplastic adipocytes, admixed with small blood vessels, and scattered inside adipose tissue spindle cells. The immunohistochemical profile revealed positivity of spindle cells for CD34, negativity for S100, and low proliferation with Ki67, which confirmed the diagnosis of spindle cell lipoma and revealed its benign behavior. INTERVENTIONS: The patient underwent hypopharyngeal mass resection using transoral suspension laryngoscopy. OUTCOMES: No recurrence was found after 5 months of follow-up. LESSONS: Spindle cell lipoma is difficult to diagnose early because of slow growth and subtle symptomatology. This entity should be differentiated from several benign or malignant subtypes of lipomas, including liposarcomas. In this case, the spindle cell lipoma is large and originates from the hypopharynx, which is a rare entity and presents with atypical symptoms. This case gave rise to further studies on the clinical and pathologic characteristics of this tumor in the future.


Assuntos
Neoplasias Hipofaríngeas/diagnóstico , Hipofaringe/patologia , Laringoscopia , Lipoma/diagnóstico , Antígenos CD34/análise , Antígenos CD34/metabolismo , Diagnóstico Diferencial , Humanos , Neoplasias Hipofaríngeas/patologia , Neoplasias Hipofaríngeas/cirurgia , Hipofaringe/diagnóstico por imagem , Hipofaringe/cirurgia , Imuno-Histoquímica , Lipoma/patologia , Lipoma/cirurgia , Lipossarcoma/diagnóstico , Masculino , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios X
2.
Aging (Albany NY) ; 13(3): 4388-4408, 2021 01 20.
Artigo em Inglês | MEDLINE | ID: mdl-33493133

RESUMO

Lumican (LUM), a small leucine-rich proteoglycan, is a component of the extracellular matrix. Abnormal LUM expression is potentially associated with cancer progression. In the present study, we confirmed high LUM mRNA expression in colorectal adenocarcinoma (COAD) through the UALCAN database. The Kaplan-Meier method, univariate, and multivariate COX analysis showed that high LUM expression is an independent determinant of poor prognosis in COAD. A COX regression model was constructed based on clinical information and LUM expression. The receiver operating characteristic (ROC) curve indicated that this model was highly accurate in monitoring COAD prognosis. The co-expression network of LUM was determined by LinkedOmics, which showed that LUM expression was closely related to immune escape and the miR200 family. Furthermore, we studied the co-expression network of LUM and found that LUM could promote tumor metastasis and invasion. The Tumor Immune Estimation Resource website showed that LUM was closely related to immune infiltration and correlated with regulatory T cells, tumour-associated macrophages, and dendritic cells. We found that LUM cultivated cancer progression by targeting the miR200 family to promote epithelial-to-mesenchymal transition. These findings suggest that LUM is a potential target for inhibiting immune escape and carcinogenic pathways.


Assuntos
Adenocarcinoma/genética , Neoplasias Colorretais/genética , Lumicana/genética , Evasão Tumoral/genética , Adenocarcinoma/imunologia , Adenocarcinoma/patologia , Neoplasias Colorretais/imunologia , Neoplasias Colorretais/patologia , Bases de Dados Genéticas , Humanos , Lumicana/imunologia , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/patologia , Prognóstico , Modelos de Riscos Proporcionais , RNA Mensageiro/metabolismo , Curva ROC , Evasão Tumoral/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...